Trial Profile

Phase I first in human study assessing AEX-2

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 04 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AEX 2 (Primary)
Indications Idiopathic hypersomnia; Narcolepsy; Neurodegenerative disorders
Focus Adverse reactions; First in man

Most Recent Events

27 Feb 2025 According to NLS Pharmaceutics media release, the study is planned to initiate by 2026.
21 Mar 2024 According to NLS Pharmaceutics media release, Aexon Labs plans phase 1 First-in-Human clinical development starting in early 2025. Preliminary findings will be unveiled at the 2024 ASCP Annual Meeting (Miami, Florida, May 28 - 31).
09 Feb 2024 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com